1.08
Atossa Therapeutics Inc 주식(ATOS)의 최신 뉴스
What moving averages say about Atossa Therapeutics Inc.2025 Trading Recap & Low Risk High Reward Ideas - newser.com
Regression analysis insights on Atossa Therapeutics Inc. performancePortfolio Gains Summary & High Accuracy Trade Signal Alerts - newser.com
What MACD and RSI say about Atossa Therapeutics Inc.July 2025 Institutional & High Conviction Buy Zone Picks - newser.com
Can Atossa Therapeutics Inc. (YAG2) stock stage a strong rebound this quarterWeekly Investment Recap & Weekly Watchlist of Top Performers - newser.com
Can a trend reversal in Atossa Therapeutics Inc. lead to recoveryEarnings Growth Report & Stepwise Swing Trade Plans - newser.com
Atossa Therapeutics and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Pueblo Chieftain
Is Atossa Therapeutics Inc. stock ready for a breakoutJuly 2025 Sector Moves & Breakout Confirmation Alerts - newser.com
How to forecast Atossa Therapeutics Inc. trends using time seriesGap Down & Weekly Market Pulse Updates - newser.com
Is Atossa Therapeutics Inc. stock entering bullish territoryMarket Growth Report & Fast Moving Stock Trade Plans - newser.com
Comparing Atossa Therapeutics Inc. in custom built stock radars2025 Earnings Surprises & Stepwise Entry and Exit Trade Signals - newser.com
Published on: 2025-10-10 02:05:17 - newser.com
Weiss Ratings Reiterates "Sell (D-)" Rating for Atossa Genetics (NASDAQ:ATOS) - MarketBeat
Can Atossa Therapeutics Inc. (YAG2) stock deliver double digit returnsOptions Play & Weekly Breakout Watchlists - newser.com
Signal strength of Atossa Therapeutics Inc. stock in tech scannersTrade Entry Report & Weekly Momentum Picks - newser.com
Can Atossa Therapeutics Inc. (YAG2) stock reach $200 price targetQuarterly Trade Report & Low Volatility Stock Recommendations - newser.com
Atossa Therapeutics (ATOS) Announces Upcoming Virtual Meeting - GuruFocus
Atossa streamlines breast cancer trial to focus on 2026 NDA plans - Investing.com
Atossa Therapeutics streamlines Evangeline breast cancer clinical trial to prioritize for 2026 NDA-enabling activities - MarketScreener
40–65-Patient EVANGELINE Redesign: Atossa Prioritizes 2026 NDA‑Enabling Activities, Reduces Study Costs - Stock Titan
Atossa Therapeutics Inc. stock retracement – recovery analysisEarnings Growth Report & Free Fast Gain Swing Trade Alerts - newser.com
Can Atossa Therapeutics Inc. stock hit analyst price targetsWeekly Risk Report & Consistent Income Trade Recommendations - newser.com
Atossa Therapeutics appoints Janet Rea as SVP of R&D By Investing.com - Investing.com Nigeria
Atossa Therapeutics appoints Janet Rea as SVP of R&D - Investing.com
What drives Atossa Therapeutics Inc YAG2 stock priceDouble Top/Bottom Patterns & Superior Trading Ideas - earlytimes.in
Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones - StreetInsider
Veteran Drug Approval Expert Returns to Atossa Therapeutics to Advance Breakthrough Breast Cancer Treatment - Stock Titan
Goldman Sachs Group Inc. Lowers Holdings in Atossa Genetics Inc. $ATOS - Defense World
NioCorp and Atossa Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Daily Jeffersonian
What analysts say about Atossa Therapeutics Inc stockSector-Based Investing & Build Capital Safely - earlytimes.in
자본화:
|
볼륨(24시간):